Hostname: page-component-54dcc4c588-gwv8j Total loading time: 0 Render date: 2025-10-13T08:06:51.776Z Has data issue: false hasContentIssue false
  • English
  • Français

The association between relapse and the outcome of schizophrenia and recurrent psychotic disorders: commentary, Moncrieff et al

Published online by Cambridge University Press:  08 September 2025

Joanna Moncrieff Open the ORCID record for Joanna Moncrieff [Opens in a new window]  and
Stefan Priebe
Joanna Moncrieff*
Affiliation:
Division of Psychiatry, University College London and North East London NHS Foundation Trust, London, UK
Stefan Priebe
Affiliation:
City St George’s, University of London, London, UK
*
Correspondence: Joanna Moncrieff. Email: j.moncrieff@ucl.ac.uk
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Keywords

Antipsychoticsrelapseschizophrenia

Information

Type
Commentary
Information
The British Journal of Psychiatry , First View , pp. 1 - 2
Check for updates
Copyright
© The Author(s), 2025. Published by Cambridge University Press on behalf of Royal College of Psychiatrists

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Trew, A, Rodda, J, Shergill, SS. The association between relapse and the outcome of schizophrenia and recurrent psychotic disorders. Br J Psychiatry 2025; this issue.CrossRefGoogle Scholar
Moncrieff, J, Pillai, E, Marston, L, Lewis, G, Barnes, TRE, Johnson, S, et al. The association between relapse and the outcome of schizophrenia and recurrent psychotic disorders. Br J Psychiatry [Epub ahead of print] 14 Apr 2025. Available from: https://doi.org/10.1192/bjp.2024.304.CrossRefGoogle Scholar
Curson, DA, Hirsch, SR, Platt, SD, Bamber, RW, Barnes, TR. Does short term placebo treatment of chronic schizophrenia produce long term harm? Br Med J (Clin Res Ed) 1986; 293: 726–8.CrossRefGoogle ScholarPubMed
Glovinsky, D, Kirch, DG, Wyatt, RJ. Early antipsychotic response to resumption of neuroleptics in drug-free chronic schizophrenic patients. Biol Psychiatry 1992; 31: 968–70.CrossRefGoogle ScholarPubMed
Almond, S, Knapp, M, Francois, C, Toumi, M, Brugha, T. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry 2004; 184: 346–51.CrossRefGoogle ScholarPubMed
Zipursky, RB, Reilly, TJ, Murray, RM. The myth of schizophrenia as a progressive brain disease. Schizophr Bull 2013; 39: 1363–72.CrossRefGoogle ScholarPubMed
Zipursky, RB, Agid, O. Recovery, not progressive deterioration, should be the expectation in schizophrenia. World Psychiatry 2015; 14: 94–6.CrossRefGoogle Scholar
Freudenthal, R, Marston, L, Stansfeld, JL, Priebe, S, Moncrieff, J. How do participants in clinical trials compare with other patients with schizophrenia? Contemp Clin Trials Commun 2021; 22: 100803.CrossRefGoogle ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.